guronelogoh.blogspot.com
Mario joins the privately held drug developmeng company from ofNew Jersey, where he was CEO. He has held managementt positions at SmithKline and Squibb and joined Glaxin 1986. He replacese Mark Platshon as CEO. During his time at Mario oversaw the launch of five major brands that grewthe company' s sales and profits by nearly 15 percenf annually, according to Palo Alto-based In 1993, he became CEO of Alza, whichh acquired in 2001.
"Ernie's extensive experiencd in all aspects of the pharmaceutica industry will be invaluablr to Capnia as we prepare to advancre our Capella treatment for migraine and rhinitidinto late-stage clinical studies," said Edgat Engleman, managing partner of , Capnia'es lead investor. Also joining Capnia are two othed pharmaceutical executives who previouslyh workedwith Mario. James Butler will be seniort vice president, marketing, and Ron Haak will be seniotr vice president, technology development. Besides Vivo Ventures of Palo Capnia backers include of Palo TeknoInvest andAlliance Venture, both of Oslo, Norway, Sagamorer Bioventures of San Francisco.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment